Date: Saturday, May 2, 2015
Session Name: Poster Session A: Liver Transplantation: Viral Hepatitis
Session Time: 5:30pm-7:30pm
Presentation Time: 5:30pm-7:30pm
Location: Exhibit Hall E
- Hepatitis C Recurrence (HCVR) in Liver Transplant Recipients (OLT): Significant Reduction in Tacrolimus (FK) Dosage Can Be Safely Achieved in Patients Rendered Aviremic after Response-Guided Therapy (RGRx) Using Telaprevir (TVR)
- Results of Response Guided Therapy (RGT) Using Telaprevir in Liver Transplant Recipients with Hepatitis C Virus (HCV) Recurrence: A Single Center Experience of 18 Patients
Aim: Liver allografts of viremic OLT have a higher risk of failure. Timely intervention is necessary. However, long-term outcome reports, especially using newer agents, is lacking. Methods: In a 10-year period, we compared: 19 OLT Rx, for 12 weeks, with TVR + Pegylated interferons (P-IFN) + Ribavirin (RBV) followed with conventional Rx (C-Rx, P-IFN+RBV) for 12-36 weeks. Controls (n=19) received C-Rx for 48 weeks. Matching done for age, gender, genotype (all 1), race, OLT date, non-responders (NR), SVR, immunosuppression (tacrolimus + Mycophenolic acid) and survival. Rx criteria HCVR histology (bx, stages 0-3, Batts&Ludwig classification). Pre and post Rx bx + annual bx and 3-year minimum follow up. Laboratory tests, graft and OLT survivals analyzed. Statitistics: t-, Chi2-tests. Results: No demographic , survival (matched controls) or laboratory differences found. Of note, 13/19 (68%) in TVR group were OLT NR to previous C-Rx. At 3+ years of follow up, there was significantly more HCVR progression in OLT TVR NR than TVR SVR (p < 0.05). Controls also showed differences in HCVR progression, although NS.
|Telaprevir + PegIFN +Ribavirin Rx||PegIFN + Ribavirin|
|Non Responders||SVR||Non Responders||SVR|
|(n = 6)||(n = 13)||(n = 6)||(n = 13)|
|Last Follow up Stage||2.7±0.8*||2.1±1.4||2.8±1.2||2.0±|
|PreRx to Last Bx Difference||1.2±0.8**||0.4±0.7**||0.8±1.0||0.2±1.1|
To cite this abstract in AMA style:Fasola C, Mantry P, Weinstein J, Nazario H, Mubarak A, Barnes M, Habib A, Mejia A, Dickerman R, Cheng S. Long-Term Outcome of Liver Transplant Recipients (OLT) With Hepatitis C Recurrence (HCVR) Who Achieved Postoperative Sustained Virologic Response (SVR) After Combination Antiviral Therapy (Rx) With and Without the Use of Telaprevir (TVR): A Single Center Experience [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/long-term-outcome-of-liver-transplant-recipients-olt-with-hepatitis-c-recurrence-hcvr-who-achieved-postoperative-sustained-virologic-response-svr-after-combination-antiviral-therapy-rx-with-an/. Accessed August 25, 2019.
« Back to 2015 American Transplant Congress